- Home >
- Clinicals Trials >
- BAYER 22615 (SOHO 02)
Lung cancer
BAYER 22615 (SOHO 02)
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.
- Open at Paris since : 19/11/2024
- Target : Adult
- Phase : Phase III
Trial description
To evaluate the effect of BAY 2927088 compared with the standard of care (SoC) in progression free survival (PFS).PFS per RECIST 1.1 as assessed by blinded independent central review (BICR)
Url of the trialMain investigator
